Vaccitech Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vaccitech Limited - overview
Established
2016
Location
Oxford, -, UK
Primary Industry
Biotechnology
About
Based in the UK, Vaccitech Limited operates as a biopharmaceutical company focused on developing innovative immunotherapeutics targeting chronic viral infections, autoimmune diseases, and cancer. Vaccitech Limited, founded in 2016 and headquartered in Oxford, UK, specializes in the development of antigen-specific immunotherapeutics. The company has raised a total of USD 110. 50 mn through six funding rounds, with its most recent deal being an IPO on April 29, 2021, which valued the firm at USD 700 mn.
The CEO's or founder's information is not provided. Vaccitech Limited's core products include VTP-200 and VTP-300, designed to treat chronic viral infections, autoimmune diseases, and cancer. VTP-200 has shown positive results in clinical trials for women with low-grade human papillomavirus-related cervical lesions, while VTP-300 has been effective in reducing Hepatitis B surface antigen in chronic Hepatitis B patients, targeting healthcare providers, hospitals, and research institutions primarily in Europe and North America. In the most recent financial year of 2023, Vaccitech Limited reported a revenue of USD 819,753.
30, with an EBITDA of USD -57,046,865. 30. The company generates revenue through partnerships and collaborations to commercialize its immunotherapeutic products, focusing on licensing agreements and clinical trials with healthcare institutions. Vaccitech Limited plans to utilize the USD 110.
50 mn raised in their recent IPO to expand its product offerings and enter new geographic markets. The firm aims to enhance its immunotherapy pipeline, including potential new product launches in the upcoming years. The expansion efforts will target North America and Europe, leveraging the growing demand for advanced therapeutic solutions. The recent funding will support ongoing clinical trials and partnerships necessary for market expansion.
Current Investors
Hong Shan, GV, Oxford Sciences Enterprises
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.vaccitech.co.uk
Company Stage
Mature
Total Amount Raised
Subscriber access only
Vaccitech Limited - financials
| Fiscal Year Ended | Jan 31, 2017 | Jan 31, 2018 | Jan 31, 2019 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 40,439 | - | 5,528,132 | 3,578,000 | 199,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | (94.4%) | - | - | - |
| EBITDA (USD) | (2,713,668) | (4,322,448) | - | (19,870,427) | (15,450,000) | (30,530,000) | - | - | - |
| Operating Income (USD) | (2,713,842) | (4,323,895) | - | (20,041,038) | (15,655,000) | (30,878,000) | - | - | - |
| Operating Margin | - | (10692.4%) | - | (362.5%) | (437.5%) | (15516.6%) | - | - | - |
| % EBITDA Margin | - | (10688.8%) | - | (359.4%) | (431.8%) | (15341.7%) | - | - | - |
| NET Income (USD) | (2,701,874) | (2,987,147) | (7,477,492) | (17,508,646) | (14,358,000) | (35,708,000) | - | - | - |
| % Net Margin | - | (7386.8%) | - | (316.7%) | (401.3%) | (17943.7%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.